Semin Arthritis Rheu: Acute respiratory viral infection during rheumatic treatment.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- COVID-19 is an acute respiratory virus infection that poses a threat worldwide, including people with rheumatism.but the extent to which rheumatoid treatment increases susceptibility to viral respiratory infections is unclear.study reviewed the incidence and severity of acute respiratory virus adverse events associated with rheumatic therapy.use an online database to find research on the main data on acute respiratory virus infection in patients with anti-rheumatism treatment.independent reviewers use standardized extract tools to pair chart data for eligible studies. A total of 180 studiesmet the criteria for qualitative analysis.Although the available literature lacks specificity in reporting acute viral infections or their complications, the data show that the use of glucocorticoids, JAK inhibitors (especially in high doses), TNF inhibitors, and anti-IL-17 drugs is associated with an increased incidence of respiratory viral infections.available data show that the use of NSAIDs, serotonin, lyunine sulfonate, methotrexate, thiopental, milolofate, cyclophosphamide or apsteadoes does not increase the incidence or risk of respiratory virus events.a large cohort study, the use of lefluorometus is associated with an increased risk of acute viral respiratory events compared to non-use.the study found that certain drugs increase the risk of acute respiratory infections.however, the lack of precise data should address this knowledge gap in future studies..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
